Furthermore, in vivo administration to Alzheimer’s disease mouse models resulted in better memory, reduced expression of inflammatory compounds (NF-κB, IL-6, IL-1β, and GFAP), and improved synaptic plasticity, mediated by synaptophysin. Here, NFKB1 is linked to early-onset autosomal dominant Alzheimer disease.